GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/phase 2 trial



Summary

This Phase 1/Phase 2 trial investigates the safety and efficacy of GD2-targeted CAR T cell therapy in patients with high-risk neuroblastoma, a challenging childhood cancer. Patients whose disease relapsed or was resistant to standard treatments received infusions of CAR T cells engineered to recognize the GD2 antigen on neuroblastoma cells. The study evaluated various dose levels and lymphodepletion regimens to optimize the therapy. Preliminary results suggest that GD2-CAR T cell therapy shows promising anti-tumor activity, leading to objective responses in some patients, and manageable toxicities. The research aims to establish the optimal CAR T cell dose and lymphodepletion strategy for improved clinical outcomes in this patient population.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!